Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Rhea-AI Summary
Xenetic Biosciences (NASDAQ: XBIO) reported first quarter 2026 results and progress on its DNase I oncology platform. Royalty revenue rose about 36% to $0.8 million, while research and development and general and administrative expenses declined.
Net loss fell to $0.5 million, with $7.3 million in cash as the company evaluates strategic alternatives.
Positive
- Royalty revenue up ~36% year-over-year to approximately $0.8 million
- Research and development expenses down ~25% to approximately $0.7 million
- General and administrative expenses down ~1.4% to approximately $0.6 million
- Net loss reduced ~49% to approximately $0.5 million for Q1 2026
Negative
- Company remains loss-making with Q1 2026 net loss of approximately $0.5 million
- Cash and cash equivalents decreased to ~$7.3 million from ~$7.9 million at year-end 2025
News Market Reaction – XBIO
In the May 13 session, XBIO gained 5.14%, reflecting a notable positive market reaction. Argus tracked a trough of -7.8% from its starting point during tracking.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | Full-year 2025 earnings | Positive | +9.5% | Royalty revenue growth, narrowed net loss, DNase program progress and investigator trials. |
| Nov 13 | Q3 2025 earnings | Positive | -2.6% | Stronger revenue and R&D ramp plus underwritten equity offering to extend cash runway. |
| Aug 13 | Q2 2025 earnings | Positive | +7.2% | Reduced operating expenses, maintained cash and expanded DNase collaborations and clinical plans. |
| May 14 | Q1 2025 earnings | Positive | +2.0% | Revenue growth, lower operating expenses and steady cash while advancing DNase platform. |
| Mar 19 | Full-year 2024 earnings | Neutral | +1.9% | Ongoing net loss with cost reductions, stable Takeda royalties and extended collaborations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have generally seen modestly positive price reactions, with only one recent quarter showing a negative move despite constructive operating updates.
Over the past year, Xenetic’s earnings updates have consistently paired DNase program progress with disciplined spending and incremental royalty growth. Full-year 2024 and 2025 results emphasized reduced R&D and G&A, stable or growing Takeda royalties, and cash balances between $4.8M and $7.9M. Quarterly reports through 2025 highlighted advancing toward Phase 1 trials and expanding collaborations. This Q1 2026 release continues that pattern, combining higher royalty revenue, a smaller net loss, and a cash position of $7.3M while the company evaluates strategic alternatives.
Key Terms
immuno-oncology medical
translational research medical
biomarker medical
car t cells medical
large b-cell lymphoma medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development
Strengthened financial profile with continued royalty revenue growth
Ended first quarter 2026 with approximately
FRAMINGHAM, MA / ACCESS Newswire / May 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform.
Recent Highlights
Generated robust translational data supporting the DNase I platform across multiple oncology settings
Completed process improvement and analytical development activities supporting future clinical manufacturing readiness
Established translational and biomarker insights intended to help inform and de-risk future clinical trial design
Collaboration partner received approval from Israeli Ministry of Health to conduct investigator-initiated exploratory study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma
"We entered 2026 with a clear focus on advancing the translational, manufacturing and clinical foundation of our DNase I platform while maintaining financial discipline," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. "During the quarter, we achieved important progress across investigator-initiated studies, translational research and manufacturing readiness activities. We believe the growing body of translational evidence supporting NET-targeting approaches, combined with the expanding understanding of NETs as drivers of tumor progression, immune suppression and therapy resistance, continues to strengthen the potential opportunity for DNase I as a differentiated adjunctive immuno-oncology therapy across multiple cancer settings."
Xenetic's proprietary DNase technology is being developed as a potential adjunctive therapeutic approach designed to improve the effectiveness of existing cancer treatments, including immunotherapies, through the targeting of NETs, which are increasingly recognized as key drivers of immune suppression and therapeutic resistance within the tumor microenvironment.
Summary of Financial Results for First Quarter 2026
Royalty revenue for the three months ended March 31, 2026 increased approximately
Research and development expenses for the three months ended March 31, 2026 decreased approximately
General and administrative expenses for the three months ended March 31, 2026 decreased by approximately
Net loss for the quarter ended March 31, 2026 decreased approximately
The Company ended the first quarter of 2026 with approximately
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding future clinical development, manufacturing readiness and trial design, our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, our belief regarding strengthening the potential opportunity for DNase I as an adjunctive therapy across multiple cancer settings and our focus on advancing DNase into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire